logo
Plus   Neg
Share
Email

Novartis' Late-stage Study On Advanced Skin Cancer Fails To Meet Primary Endpoint

Novartis (NVS) said that that a late-stage study, which evaluated the investigational immunotherapy spartalizumab in combination with Tafinlar and Mekinist, did not meet its primary endpoint for patients with advanced skin cancer.

The Phase III COMBI-i study did not improve progression-free survival in previously untreated patients with BRAF V600 mutation-positive cutaneous melanoma, compared to Tafinlar + Mekinist alone, the company said in a statement.

However, the company said it remains committed to exploring new uses for immunotherapy in cancer treatment, including the ongoing development of spartalizumab, across a range of tumor types.

Novartis noted that Tafinlar and Mekinist are prescription medicines that can be used in combination to treat people with a type of skin cancer called melanoma.

Tafinlar and Mekinist are also prescription medications that can be used in combination to treat a type of lung cancer called non-small cell lung cancer that has spread to other parts of the body.

Tafinlar and Mekinist are prescription medications that can be used in combination to treat a type of thyroid cancer called anaplastic thyroid cancer.

Novartis warned that Tafinlar, in combination with Mekinist, should not be used to treat people with wild-type BRAF melanoma. Mekinist should not be used to treat people who already have received a BRAF inhibitor for treatment of their melanoma and it did not work or is no longer working.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Eli Lilly and Co. (LLY) will end a phase III clinical trial for its COVID-19 antibody treatment in the U.S., due to insufficient evidence on improved clinical outcomes. Orca Bay Foods, LLC recalled about 4,450 pounds of Trader Joe's brand Gluten Free Battered Halibut products for undeclared wheat and milk allergens, according to a statement published by the U.S. Food and Drug Administration (FDA). The action was initiated after it was discovered that product containing Wheat and Milk was distributed in packaging. Lee Kun-hee, the Chairman of South Korean conglomerate Samsung Group, has died on October 25, at the age of 78. It was he who transformed Samsung into a South Korean behemoth, and the world's largest manufacturer of smartphones, televisions, and semiconductors. As per reports, Lee's only son Jae-yong, who currently serves as vice chairman of Samsung Electronics, is likely to take over Samsung.
Follow RTT